Cargando…

Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease

The aim of the present study was to determine whether the expression levels of interleukin (IL)-2 and IL-10 may be used as biological markers in Graves’ disease (GD) patients. A total of 256 individuals, including 118 GD patients and 138 healthy individuals, were enrolled into the study. Blood sampl...

Descripción completa

Detalles Bibliográficos
Autores principales: LIANG, CUIGE, DU, WENHUA, DONG, QINGYU, LIU, XIAOMENG, LI, WENXIA, WANG, YUELI, GAO, GUANQI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316959/
https://www.ncbi.nlm.nih.gov/pubmed/25667655
http://dx.doi.org/10.3892/etm.2015.2180
_version_ 1782355649196195840
author LIANG, CUIGE
DU, WENHUA
DONG, QINGYU
LIU, XIAOMENG
LI, WENXIA
WANG, YUELI
GAO, GUANQI
author_facet LIANG, CUIGE
DU, WENHUA
DONG, QINGYU
LIU, XIAOMENG
LI, WENXIA
WANG, YUELI
GAO, GUANQI
author_sort LIANG, CUIGE
collection PubMed
description The aim of the present study was to determine whether the expression levels of interleukin (IL)-2 and IL-10 may be used as biological markers in Graves’ disease (GD) patients. A total of 256 individuals, including 118 GD patients and 138 healthy individuals, were enrolled into the study. Blood samples were collected from each patient and healthy individual, which were then subjected to enzyme-linked immunosorbent assay (ELISA). Total RNA and total proteins were determined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively. In addition, restriction fragment length polymorphism (RFLP) analysis was performed to detect the presence of genetic polymorphisms. The ELISA results indicated that the IL-2 and IL-10 serum levels in the GD patients were increased by ~5.2 and ~7-fold when compared with the levels in the healthy controls. The results of RT-qPCR indicated that the mRNA expression levels of IL-2 and IL-10 were upregulated in the GD patients when compared with the healthy controls. Furthermore, the western blot analysis results revealed that the protein expression levels of IL-2 and IL-10 were significantly increased in the GD patients. RFLP analysis indicated that the increased number of GG single nucleotide polymorphisms (SNPs) in the GD group were detected in the −330 locus of the IL-2 promoter and the −1082 locus of the IL-10 promoter. In addition, the results indicated that the relatively high rates of homozygous GG SNPs (IL-2 −330T/G and IL-10 −1082A/G polymorphisms) on the alleles may be associated with the incidence of GD. The serum, mRNA and protein expression levels of IL-2 and IL-10 were significantly increased in GD patients when compared with the levels in the healthy controls. In conclusion, the expression levels and genetic polymorphisms of IL-2 and IL-10 may be potential biomarkers for the incidence of Graves’ disease in the population studied.
format Online
Article
Text
id pubmed-4316959
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-43169592015-02-09 Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease LIANG, CUIGE DU, WENHUA DONG, QINGYU LIU, XIAOMENG LI, WENXIA WANG, YUELI GAO, GUANQI Exp Ther Med Articles The aim of the present study was to determine whether the expression levels of interleukin (IL)-2 and IL-10 may be used as biological markers in Graves’ disease (GD) patients. A total of 256 individuals, including 118 GD patients and 138 healthy individuals, were enrolled into the study. Blood samples were collected from each patient and healthy individual, which were then subjected to enzyme-linked immunosorbent assay (ELISA). Total RNA and total proteins were determined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively. In addition, restriction fragment length polymorphism (RFLP) analysis was performed to detect the presence of genetic polymorphisms. The ELISA results indicated that the IL-2 and IL-10 serum levels in the GD patients were increased by ~5.2 and ~7-fold when compared with the levels in the healthy controls. The results of RT-qPCR indicated that the mRNA expression levels of IL-2 and IL-10 were upregulated in the GD patients when compared with the healthy controls. Furthermore, the western blot analysis results revealed that the protein expression levels of IL-2 and IL-10 were significantly increased in the GD patients. RFLP analysis indicated that the increased number of GG single nucleotide polymorphisms (SNPs) in the GD group were detected in the −330 locus of the IL-2 promoter and the −1082 locus of the IL-10 promoter. In addition, the results indicated that the relatively high rates of homozygous GG SNPs (IL-2 −330T/G and IL-10 −1082A/G polymorphisms) on the alleles may be associated with the incidence of GD. The serum, mRNA and protein expression levels of IL-2 and IL-10 were significantly increased in GD patients when compared with the levels in the healthy controls. In conclusion, the expression levels and genetic polymorphisms of IL-2 and IL-10 may be potential biomarkers for the incidence of Graves’ disease in the population studied. D.A. Spandidos 2015-03 2015-01-14 /pmc/articles/PMC4316959/ /pubmed/25667655 http://dx.doi.org/10.3892/etm.2015.2180 Text en Copyright © 2015, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
LIANG, CUIGE
DU, WENHUA
DONG, QINGYU
LIU, XIAOMENG
LI, WENXIA
WANG, YUELI
GAO, GUANQI
Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease
title Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease
title_full Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease
title_fullStr Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease
title_full_unstemmed Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease
title_short Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease
title_sort expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of graves’ disease
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316959/
https://www.ncbi.nlm.nih.gov/pubmed/25667655
http://dx.doi.org/10.3892/etm.2015.2180
work_keys_str_mv AT liangcuige expressionlevelsandgeneticpolymorphismsofinterleukin2andinterleukin10asbiomarkersofgravesdisease
AT duwenhua expressionlevelsandgeneticpolymorphismsofinterleukin2andinterleukin10asbiomarkersofgravesdisease
AT dongqingyu expressionlevelsandgeneticpolymorphismsofinterleukin2andinterleukin10asbiomarkersofgravesdisease
AT liuxiaomeng expressionlevelsandgeneticpolymorphismsofinterleukin2andinterleukin10asbiomarkersofgravesdisease
AT liwenxia expressionlevelsandgeneticpolymorphismsofinterleukin2andinterleukin10asbiomarkersofgravesdisease
AT wangyueli expressionlevelsandgeneticpolymorphismsofinterleukin2andinterleukin10asbiomarkersofgravesdisease
AT gaoguanqi expressionlevelsandgeneticpolymorphismsofinterleukin2andinterleukin10asbiomarkersofgravesdisease